{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=sorafenib+with+temsirolimus", "query": { "intervention": "sorafenib with temsirolimus" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 22, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=sorafenib+with+temsirolimus&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T14:03:12.718Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00335764", "title": "Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Recurrent Adult Brain Tumor" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" }, { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "tipifarnib", "type": "DRUG" }, { "name": "temsirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2006-04", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2018-07-02", "last_synced_at": "2026-10-01T14:03:12.718Z", "location_count": 7, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00335764" }, { "nct_id": "NCT02560012", "title": "Personalized Targeted Inhibitors Treatment in Renal Cell Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Sunitinib", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Pazopanib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Axitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2016-01-04", "completion_date": "2017-07-27", "has_results": true, "last_update_posted_date": "2018-10-12", "last_synced_at": "2026-10-01T14:03:12.718Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02560012" }, { "nct_id": "NCT00474929", "title": "Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 103, "start_date": "2007-08-29", "completion_date": "2019-08-08", "has_results": true, "last_update_posted_date": "2019-08-20", "last_synced_at": "2026-10-01T14:03:12.718Z", "location_count": 2, "location_summary": "Iowa City, Iowa • Rochester, Minnesota", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00474929" }, { "nct_id": "NCT00449280", "title": "Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "Sorafenib", "type": "DRUG" }, { "name": "Rapamycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2006-11", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2013-06-12", "last_synced_at": "2026-10-01T14:03:12.718Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00449280" }, { "nct_id": "NCT02551718", "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Recurrent Acute Leukemia of Ambiguous Lineage", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Acute Leukemia of Ambiguous Lineage" ], "interventions": [ { "name": "Chemosensitivity Assay", "type": "OTHER" }, { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Gene Expression Analysis", "type": "GENETIC" }, { "name": "Genetic Variation Analysis", "type": "GENETIC" }, { "name": "In Vitro Sensitivity-Directed Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "OTHER", "GENETIC", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 34, "start_date": "2015-09-11", "completion_date": "2021-05-13", "has_results": true, "last_update_posted_date": "2022-06-30", "last_synced_at": "2026-10-01T14:03:12.718Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02551718" }, { "nct_id": "NCT00255658", "title": "Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" }, { "name": "temsirolimus", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2005-09", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2015-04-15", "last_synced_at": "2026-10-01T14:03:12.718Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00255658" }, { "nct_id": "NCT00329719", "title": "Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Glioblastoma", "Adult Gliosarcoma", "Recurrent Adult Brain Neoplasm" ], "interventions": [ { "name": "Conventional Surgery", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Sorafenib Tosylate", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2006-03-24", "completion_date": "2013-02-02", "has_results": true, "last_update_posted_date": "2018-10-16", "last_synced_at": "2026-10-01T14:03:12.718Z", "location_count": 190, "location_summary": "Anchorage, Alaska • Scottsdale, Arizona • Hartford, Connecticut + 118 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT00329719" }, { "nct_id": "NCT00474786", "title": "Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Sorafenib", "type": "DRUG" }, { "name": "temsirolimus (Torisel)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 512, "start_date": "2007-09", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2013-11-21", "last_synced_at": "2026-10-01T14:03:12.718Z", "location_count": 26, "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 19 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00474786" }, { "nct_id": "NCT00498966", "title": "Ph II Study of Perifosine for Patients With Carcinoma of the Kidney", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "Perifosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AEterna Zentaris", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2007-07", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2018-02-05", "last_synced_at": "2026-10-01T14:03:12.718Z", "location_count": 3, "location_summary": "Louisville, Kentucky • Morristown, New Jersey • Armonk, New York", "locations": [ { "city": "Louisville", "state": "Kentucky" }, { "city": "Morristown", "state": "New Jersey" }, { "city": "Armonk", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00498966" }, { "nct_id": "NCT01223027", "title": "Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "Dovitinib", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 564, "start_date": "2011-03", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2015-12-07", "last_synced_at": "2026-10-01T14:03:12.718Z", "location_count": 34, "location_summary": "Fayetteville, Arkansas • La Jolla, California • Los Angeles, California + 26 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01223027" } ] }